A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

Autor: Lingfang Xia, Qi Zhou, Yunong Gao, Wenjing Hu, Ge Lou, Hong Sun, Jianqing Zhu, Jin Shu, Xianfeng Zhou, Rong Sun, Xiaohua Wu
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Druh dokumentu: article
ISSN: 2041-1723
DOI: 10.1038/s41467-022-35133-4
Popis: Patients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or metastatic squamous cervical cancer.
Databáze: Directory of Open Access Journals